Report: Latin American diabetes therapeutics market to transform
“The Latin American diabetes therapeutics market will experience major changes within the next three years due to the launch of innovative drugs that include three long-acting insulins and four non-insulin treatments. Nevertheless, pharmaceutical companies should continue their research to develop treatments that can restore beta-cell function and thereby postpone or prevent disease progression—areas that even newer therapies do not address.
New analysis from Frost & Sullivan, Trends, Opportunities, and Challenges for the Latin American Diabetes Therapeutics Market, expects the diabetes therapeutics market to grow, due to the rising prevalence of diabetes in the region. Improved awareness among patients on the importance of early diagnosis and treatment of diabetes will ensure steady market growth in the next five years. The research covers non-insulin and insulin therapeutics.”